a National Center for Immunization and Respiratory Diseases , Centers for Disease Control and Prevention , Atlanta , GA , USA.
Hum Vaccin Immunother. 2018;14(10):2460-2463. doi: 10.1080/21645515.2018.1480283. Epub 2018 Jul 16.
We reported previously that the annual average mortality rate in the United States in 2008-2011 for varicella listed as the underlying cause declined 87% compared with the prevaccine period (1990-1994). Here, we update the analysis with five additional years of data. We used varicella death data from the 2012-2016 Mortality Multiple Cause-of Death records to calculate mortality rates during 2012-2016 and trends since the prevaccine period and end of 1-dose vaccination program (2005-2007). The annual average age-adjusted mortality rate for varicella as the underlying cause was 0.03 per million population during 2012-2016, a 94% reduction from prevaccine years and a 47% reduction from 2005-2007. Varicella deaths continue to decline due to the varicella vaccination program in the United States.
我们曾报道过，2008-2011 年美国因水痘列为根本死因的年平均死亡率与疫苗前时期（1990-1994 年）相比下降了 87%。在此，我们用另外五年的数据对分析进行了更新。我们使用了 2012-2016 年死亡率多重死因记录中的水痘死亡数据，计算了 2012-2016 年的死亡率以及自疫苗前时期和 1 剂疫苗接种计划结束以来（2005-2007 年）的趋势。2012-2016 年，水痘作为根本死因的年龄调整后年平均死亡率为每百万人口 0.03 例，与疫苗前时期相比下降了 94%，与 2005-2007 年相比下降了 47%。由于美国的水痘疫苗接种计划，水痘死亡人数继续下降。
